ArticleCardio-oncology (London, England)2026
Inflammation mediates platinum-based chemotherapy-induced risk of adverse cardiac events in older NSCLC patients: a pilot study.
Article in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundChemotherapy increases the risk of cardiovascular toxicity, leading to adverse cardiac events (ACEs) in cancer patients. However, the underlying mechanisms and roles of mediators in this association remain poorly understood.
objectivesThis study aimed to investigate the mediating role of inflammation in the association between platinum-based chemotherapy (PBC) and increased risk of ACEs in older patients with non-small cell lung cancer (NSCLC).
methodsWe retrospectively analyzed data from NSCLC patients aged ≥ 50 years, initially diagnosed between 2018 and 2020 at our institution. The treatment group included patients who received PBC, whereas the control group consisted of patients who did not. The mediator was the maximum neutrophil-to-lymphocyte ratio (NLR) measured between initial chemotherapy and one year after diagnosis. The outcome was the occurrence of ACEs during follow-up period. Causal mediation analysis was conducted to assess the mediating effect of a clinically meaningful inflammatory response on the PBC-ACE association.
resultsAmong the 1,450 patients included (55% male, 45% female; median age: 61.6 years), 242 (16.7%) developed ACEs during the follow-up. The average direct effect was similar across both groups (control: 0.050, p = 0.018; treatment: 0.052, p = 0.018), indicating the consistent direct impact of PBC on the occurrence of ACE. However, the proportion of the total effect mediated by inflammation was higher in the treatment group (11.83%, p = 0.01) than that in the control group (9.12%, p = 0.01). Additionally, the average causal mediation effect was greater in the treatment group (0.0067, p < 0.01) than in the control group (0.0052, p < 0.001).
conclusionsInflammation plays a crucial role in mediating the association between PBC and increased risk of ACEs in older patients with NSCLC. The mediating effect was more prominent in patients receiving PBC, emphasizing the need to monitor and manage inflammation to mitigate cardiovascular risks in patients with NSCLC undergoing PBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.